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A B S T R A C T   
This article provides prospective appraisal of key policy instruments intended to stimulate innovation to combat 
antimicrobial resistance (AMR). AMR refers to the ability of microbes to evolve resistance to those treatments 
designed to kill them, and is associated with the overuse or misuse of medicines such as antibiotics. AMR is an 
emerging global challenge with major implications for healthcare and society as a whole. Diagnostic tests for 
infectious diseases can guide decision making when prescribing medicines, so reducing inappropriate drug use. 
In the context of growing international interest in policies to stimulate innovation in AMR diagnostics, this study 
uses multicriteria mapping (MCM) to appraise a range of policy instruments in order to understand their po-
tential performance while also highlighting the uncertainties that stakeholders hold about such interventions in 
complex contexts. A contribution of the article is the demonstration of a novel method to analyse and visualise 
MCM data in order to reveal stakeholder inclinations towards particular options while exploring interviewees’ 
uncertainties about the effectiveness of each instrument’s design or implementation. The article reports results 
from six European countries (Germany, Greece, Italy, the Netherlands, Spain and the UK). The findings reveal 
which policy instruments are deemed most likely to perform well, and why, across stakeholder groups and 
national settings, with areas of common ground and difference being identified. Importantly, the conclusions 
presented here differ from prominent policy discourse, with international implications for the design of mixes of 
policy instruments to combat AMR. Strategic and practical methodological implications also emerge for general 
appraisal of innovation policy instrument mixes.   
1. Introduction 
This article provides prospective appraisal of key policy instruments 
intended to stimulate innovation to combat antimicrobial resistance 
(AMR), using a novel multicriteria analysis within a generalisable 
framework for the analysis of policy instrument mixes. In doing so, the 
article provides important insights for the study of innovation policy as 
well as offering a contribution to policy making in relation to an 
emerging global challenge for healthcare and society as a whole. 
The establishment of Pasteur’s Germ Theory in the late 19th century 
led to the development of a wide range of medicines targeting 
pathological microorganisms, leading to a great reduction in mortality 
rates from infectious disease globally (Porter, 1999; Kingston, 2000). 
However, resistance to antimicrobial drugs generally emerges following 
their widespread use, threatening therapeutic effectiveness (Sharma and 
Towse, 2011; Bell et al., 2014). AMR has recently been estimated to cause 
more than 23,000 deaths per annum in the USA and over 25,000 in the EU 
(CDDEP, 2015). Despite longstanding difficulties in estimating the cur-
rent and future burden of AMR globally, such attempts are nonetheless 
associated with a scenario, widely disseminated by senior medical ex-
perts, of a global ‘antibiotic apocalypse’, which threatens the practice of 
modern medicine, whereby routine procedures such as chemotherapy 
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and surgical operations would be too dangerous to undertake without 
anti-infective drugs (Smith and Coast, 2012, 2013; Davies et al., 2013; 
Wellcome Trust, 2019).1 The World Health Organisation (WHO), the 
European Union (EU), and many national governments have launched 
AMR action plans with aims including the reduction of antibiotic use in 
agriculture and human healthcare, as well as the ramping up of innova-
tion for anti-infective drugs, vaccines and diagnostic tests (Federal Min-
istry of Health, 2008; DH and DEFRA, 2013; The White House, 2015; 
WHO, 2015; EHP Committee on AMR, 2016). 
This article focuses specifically on the appraisal of policy instruments 
to support the development and use of diagnostic tests to manage AMR. 
Diagnostics are not generally the primary focus of AMR responses. For 
example, in European countries, R&D efforts have focused to a much 
greater extent on new therapeutics, including, but not limited to, new 
antibiotics (Kelly et al., 2016). Yet such therapeutics are expensive and 
slow to develop (Czaplewski et al., 2016). They also require public 
subsidies of hundreds of millions of dollars to stimulate commercial 
interest because many pharmaceutical firms have moved away from 
antibiotic R&D over recent years to focus on more profitable markets 
such as cancer (Sharma and Towse, 2011; Ferraro et al., 2017; Towse 
et al., 2017). Furthermore, resistance to new antimicrobial drugs tends 
to develop within a few years of introduction and correlates with levels 
of drug usage (ibid), suggesting that the development of new drugs alone 
will not provide a sustainable solution to the AMR challenge. 
Diagnostic tests that can distinguish bacterial infection from other 
forms of illness and determine the presence of antibiotic resistance are 
important to provide public health surveillance and to guide the medical 
treatment of individuals, potentially avoiding unnecessary use or over-
use of antibiotics (O’Neill, 2015). Such tests do not face the same reg-
ulatory hurdles as novel drugs (Phillips, Bebber and Issa, 2006) and so 
may reach the market more swiftly. However, a recent review of di-
agnostics for AMR concluded that innovation has been slow and the 
uptake of new tests has been limited (O’Neill, 2015). Many policy rec-
ommendations have been made to address this challenge (Spellberg 
et al., 2011; O’Neill, 2015; CDC and AdvaMedDx, 2016), but there is as 
yet little extant literature that provides evaluation of the effectiveness of 
such a wide range of policy options. 
With so many countries facing the AMR challenge, this article aims to 
support the development of innovation policy to counter AMR by 
providing a novel method for policy appraisal based on multicriteria 
mapping (MCM), which is then applied to six European countries. The 
method gives diverse stakeholders in these six countries the opportunity 
to appraise policy options intended to stimulate diagnostic innovation in 
support of a national AMR strategy. The overarching question asks, by 
reference to a range of national settings and stakeholder perspectives, 
which policy instruments are expected to perform more or less 
favourably, under which conditions and why? Findings in this regard 
might support practical prioritisation of policy instruments in national 
AMR action plans. 
Despite illuminating some crucial differences across both settings and 
perspectives, this study also identifies some notable common ground in 
terms of the outcomes of the appraisal, particularly across interviewees 
from the larger European countries. This picture of convergent stake-
holder inclinations towards particular policy instruments – including 
their use in combination – is all the more compelling for arising from a 
method that attends so carefully to revealing differences in perspectives. 
In this article we use the term ‘perspective’ to refer to “a grouping of 
viewpoints that may be seen on the basis of MCM analysis to display 
certain features in common” (Coburn et al., 2019). Individual view-
points can be grouped into perspectives in different ways, e.g. by their 
country setting or by their stakeholder group. 
Applying MCM in a new field and manner, the article also tests a 
novel general method for appraising prospective policy instrument 
mixes. A crucial feature of this approach is the systematic exploration of 
uncertainties across diverse settings and stakeholder perspectives. 
Respecting key principles both of quantitative and qualitative rigour, 
this process provides a picture of comparative performance that is both 
systematic and reproducible in its scope, as well as more nuanced in its 
attention to ever-present subjectivity and conditionality (Goertz and 
Mahoney, 1996; Mingers, 1997; Shah and Corley, 2006; Porta and 
Keating, 2008; Delyser and Sui, 2014). Section 2 sets out the associated 
conceptual framework for prospective appraisal of innovation policy 
options and discusses practicalities for its implementation. A series of 
sub-questions are identified, which stem from the framing of the over-
arching research question above in the innovation policy literature. 
Sections 3 and 4 introduce the research design and methods used. Sec-
tion 5 reports the findings of the empirical research, while Section 6 
provides the discussion of these results both in the context of wider ef-
forts to address AMR and the literature on the evaluation of innovation 
policy more generally. Conclusions are drawn on the implications of the 
findings, noting limitations of this study and opportunities for further 
research. 
2. Appraising innovation policy instruments 
This article’s aim is to identify those changes in policy that might 
best enable the most effective forms of innovation in AMR diagnostics 
across contrasting national settings and stakeholder perspectives. To 
meet this aim, it is necessary to address certain challenges in con-
ceptualising and analysing innovation policy. Here, a range of ap-
proaches across a wide literature (OECD, 2010), suggests a short but 
usefully broad understanding of ‘innovation policy’ (in any given area), 
as “all policies that have an impact on innovation” (in that area) (Fager-
berg, 2016). This includes policy impacts that may be indirect as well as 
direct (Dutrenit et al., 2013) and unintended as well as deliberate 
(Fagerberg and Mowery, 2009), and it requires going “beyond the sectoral 
approach” (OECD, 2005) to focus on the most relevant “policy mix” 
(Rogge and Reichardt, 2013) for promoting (in this case) effective 
innovation in AMR diagnostics. So, even under a particular viewpoint or 
in a very specific setting like this, the task is not simply about identifying 
a single ‘best policy’ (Kern and Howlett, 2009), but exploring an array of 
alternatives and their various possible conditions, interactions and 
contextual implications (Rogge and Reichardt, 2016). 
A further challenge rests on the levels of diversity, uncertainty, 
contestation and historic path-dependency that typically affect innova-
tion policy (Smits, Kuhlmann and Shapira, 2010) – especially in a field 
as complex as AMR diagnostics (Nesta, 2018; WHO, 2018; DHSC and 
DEFRA, 2019). This complexity extends even to notionally singular 
‘policies’ which should (for the sake of rigour and accuracy) be recog-
nised actually to comprise a number of more specific ‘instruments’ 
(Cunningham et al., 2013). Moreover, performance of each of these will 
typically be context-dependent, as instruments interact in complex ways 
(Rogge and Reichardt, 2016), resulting in complementarities and con-
flicts (Flanagan and Uyarra, 2016). Some instruments may depend on 
other instruments or particular local resources in order to be effective 
(Gunningham and Sinclair, 1999; Cunningham et al., 2013). Solutions in 
one country or system cannot therefore be expected to ‘travel well’ to 
others because their effectiveness is dependent on so many contextual 
interactions (Nelson, 2008; Mazzucato, 2018). 
Similarly no ‘one-size-fits-all’ instrument mix is to be expected, even 
when looking at the same problem in different contexts (Borrás and 
Edquist, 2013). This may be because instruments are selected and their 
design is shaped locally by policy makers in response to the needs of 
powerful lobbies, political ideologies and macroeconomic conditions 
(Nelson and Winter, 1982; Borrás and Edquist, 2013; Hopkins et al., 
2019). Moreover, different mixes of instruments are warranted over 
time, following the maturity of the market and changing bottlenecks, 
1 ‘All you need to know about the antibiotic apocalypse’, BBC News website, 
10th October (Nogrady, 2016); ‘Antibiotic Apocalypse: Doctors sound warning 
over drug resistance’, The Observer, 8th October (McKie, 2017). 
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such as missing capabilities or connectivity, and these require attention 
at different times and perhaps involving different actors (Neij, 1999; 
Cunningham et al., 2013). The granularity of any enquiry seeking to 
identify the best array of interventions for promoting effective innova-
tion in AMR diagnostics is thus most robustly constituted not by ‘inno-
vation policies’ in general, but more precisely at the level of what might 
be called the relevant ‘policy instrument mix’ (Borrás and Edquist, 2013; 
Kivimaa and Kern, 2016). It is therefore at the level of specific in-
struments, rather than more general policies, that this article begins. 
Even so, however, no single instrument – let alone any mix – can be 
so definitively specified, nor any context so carefully defined, that 
these are not in turn also seriously complicated by many intrinsic and 
unavoidable forms of variability, uncertainty and complex dynamics 
over time (Edmondson et al., 2018). Furthermore, efforts to provide 
rigour and precision in the characterisation of instruments, will 
nonetheless likely be perceived with ambiguity across diverse per-
spectives (Rogge and Reichardt, 2016). As a result, radically divergent 
stakeholder understandings (and thus appraisals) can be expected 
(Raven et al., 2017), with each apparently equally salient, valid and 
well-informed (Stirling, 2010). 
Methods of appraisal should address in a systematic and rigorous 
way the challenge of divergent stakeholder views (Stirling, 2008b). This 
may involve resisting well-recognised pressures for justification in pol-
icy appraisal (Genus and Stirling, 2017), where political pressures to 
deliver single ‘simple answers’ and ‘elevator messages’ may force sup-
pression of deep uncertainties and ambiguities. ‘Risks’ for instance, are 
misleadingly aggregated using probabilistic techniques, potentially 
providing erroneous impressions of confidence (Funtowicz and Ravetz, 
1990; Wynne, 1992). In such ways, the ‘closing down’ of policy dis-
cussion may result from misleading assertions of a particular view as if it 
were somehow distinctively valid or robust (Stirling, 2008b). 
It is unfortunate in the face of such challenges, that both retrospec-
tive evaluation and prospective appraisal of instrument mixes presently 
remain at an early stage of development (Cunningham et al., 2013). 
Indeed, it has recently been pointed out that system-oriented innovation 
policy more generally, remains an under-researched topic (Borrás and 
Laatsit, 2019). Yet, the importance of tailored and holistic thinking for 
instrument mixes is – for all the above reasons – increasingly compelling. 
For example, the OECD (2016b) reports that there is a global trend to-
wards countries moving away from generic ‘policy mixes’ towards more 
tightly-focused sector- and technology-specific interventions, inte-
grating both supply and demand sides. Here, there is an especially 
intense need for methodological innovation in order to address urgent 
needs for robust approaches to support developing instrument mixes for 
innovation policy (Borrás and Edquist, 2013; Cunningham et al., 2013). 
It is against this background that this article seeks to contribute to the 
prospective appraisal of policy mixes for AMR diagnostic innovation. 
To this end, the above discussion suggests a number of methodo-
logical design criteria to make the proposed appraisal as rigorous and 
robust as possible. Taking each of the above points in turn, these criteria 
might be summarised as follows. 
First, the methods used should be holistic in scope, capable of 
addressing a diverse array of contexts without undue privilege to any 
particular setting (e.g. high- or middle-income countries, ‘free market’ 
or more regulated economies). Second, the methods should be able to 
address a diversity of options, without unduly favouring particular kinds 
of intervention (e.g. public or private, supply- or demand-side, or 
technology- or organisationally based innovations). 
Third, rather than being hardwired to identify a notionally single 
‘best’ prescription, appraisal should be capable of addressing in-
teractions, complementarities and tensions across portfolios of possible 
options (i.e. leaving open the possibility for finding mixes, not single 
interventions). Fourth, the approach should engage with salient con-
ditionalities in respect of particular features of options, contexts or the 
unfolding of time (e.g. interrogation at the granularity of particular 
instruments rather than general policies). 
Fifth, policy appraisal should avoid pretensions at deriving a sup-
posedly uniquely ‘objectively valid’ picture – and instead give balanced 
attention to a plurality of relevant specialist understandings and per-
spectives (e.g. fairly engaging disparate stakeholder interests). Sixth, 
with respect to each such perspective, the method should be capable of 
addressing uncertainties (e.g. exploring the full range of possibilities for 
how innovations or their contexts may unfold over time, without arti-
ficial probabilistic aggregations). 
More generally, these methodological design criteria suggest a need 
to appreciate limits to probabilistic techniques, which is also relevant in 
interpreting policy-relevant results (Collingridge, 1982), as will be seen 
later. In any complex policy appraisal, ambiguities arise concerning the 
dimensionalities, definitions and partitioning of categories of interest 
(like relevant populations, salient parameters, causal mechanisms or 
frequency distributions) (Stirling, 2010). Even when proposing cate-
gories of interest, eliciting whether the effects of an intervention apply 
to all categories and conditionalities does not lie in ‘statistical repre-
sentativeness’ (Rothman et al., 2013). This means not only that this 
conventional aim in much quantitative research is difficult to achieve in 
practice, but also that statistical representativeness would not fully 
enable the exploration of conditionalities nor satisfy democratic repre-
sentativeness (O’Neill, 2001). 
Taking these considerations together, this article not only seeks 
directly to address the concrete – urgent and imperative – global policy 
challenge of supporting innovation in diagnostic testing to mitigate 
AMR, but also to address an additional methodological aim. In resolving 
the above criteria, it sets out to build on past practice in order to pilot a 
particular novel framework for prospective appraisal of innovation 
policy options, which attempts to address all the aforementioned 
demanding challenges. To the extent the above six criteria can be 
respected, the resulting framework should be of relevance in principle to 
decision making processes across a wide array of innovation policy 
challenges. 
3. Process for the prospective appraisal of innovation policy 
instrument mixes 
3.1. Design of method 
For reasons well-articulated by Borrás and Edquist (2013), this study 
tests an implementation of the three stage process advocated for pro-
spective appraisal of instrument mixes in innovation policy design. 
These stages comprise: (1) selection of instruments from a wide range of 
possible candidates; (2) customisation of these instruments to fit with 
particular aspects of relevant contexts; (3) design of specific resulting 
mixes of instruments. While Borrás and Edquist (2013) provide an 
overarching framework for innovation policy design there has been little 
attention to the methodology for undertaking systematic prospective 
appraisal of innovation policy instruments (Fagerberg, 2016). 
It is recognised, including by Borrás and Edquist (2013), that such an 
approach should be based within a wider framework for ‘strategic fore-
sight’ of innovation policy (Velamoor, 2000). Here, possible in-
terventions should be appraised by a diverse range of stakeholders with 
salient expertise in relevant settings (Giaoutzi and Sapio, 2013). It is in 
this context, that the six specific criteria mentioned above are emphasised 
as central to designing the method of appraisal for instrument mixes, such 
as for diagnostic innovation to manage AMR. 
An array of potentially relevant approaches have been developed 
explicitly in broad fields for policy appraisal (Roe, 1994; Nagel, 2002), 
decision analysis (Edwards, Miles and Winterfeldt, 2007), strategic in-
telligence (Kuhlmann, 2002), research evaluation (Fahrenkrog et al., 
2002), innovation management (Shane, 2008) and technology assess-
ment (Rip, Misa and Schot, 1995; Grin et al., 1997; Sclove, 2010). 
Despite many differences of detail – and a measure of ‘boundary work’ 
between disciplines and policy sectors (Yoshizawa, 2007) – a wide 
subset of these offer relevant frameworks for present purposes that: (a) 
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characterise diverse possible options towards some focal policy goal; (b) 
distinguish the issues, values or settings most relevant to appraising 
these options; (c) explore the pros and cons of each option across rele-
vant circumstances; (d) do all this under each of a number of divergent 
evaluative perspectives by involving a wide range of participants; (e) in 
order to yield a general merit ordering across all included options that 
takes these aspects into account (Ely et al., 2014). 
With respect to the policy challenges highlighted in the last section, 
however, the resulting specific methods differ in their various abilities 
to: (f) maximise the agency of participants in framing their own ap-
praisals and how they are interpreted and represented; (g) giving 
balanced consideration to qualitative as well as quantitative informa-
tion; (h) deliberately elicit relevant uncertainties under each included 
perspective; (i) clearly illuminate ambiguities that arise from 
comparing divergent perspectives; (j) explicitly focus on trade-offs be-
tween different evaluative criteria (or alternative ways of being rational 
about contending priorities); (k) examining the extent and ways in 
which different options might relate to each other in a mix; and (l) 
respecting needs for transparency and accountability to third parties 
concerning the particular reasons why appraisal results take the forms 
they do (Ely et al., 2014). 
Among the relatively few approaches that maximise these more 
specific qualities for policy appraisal, the well-established multicriteria 
mapping (MCM) method is prominent and favourably reviewed (POST, 
2001; Yearley, 2001; Anon, 2004; Dodgson et al., 2009) across scores of 
policy appraisals undertaken in many sectors and countries (Stirling and 
Mayer, 2001; Burgess, 2004, 2007; Stirling et al., 2007, 2008a; Brooks 
et al., 2009; Eames and McDowall, 2010; Hansen, 2010; Morgan Jones, 
2010; Bellamy et al., 2013; Raven et al., 2017). MCM shares with other 
decision analysis methods the core elements of rigour listed under fea-
tures (a) to (e) above, whilst also adopting an approach as open and 
unconstrained as possible in addressing the additional qualities (f) to (l) 
(Coburn and Stirling, 2016). Indeed, MCM has been specifically 
designed to enable both the ‘broadening out’ of the scope of what is taken 
into account (as inputs to policy appraisal) (Stirling, 1999); as well as the 
‘opening up’ of the picture that is conveyed to wider political discussion 
(as outputs from appraisal) (Stirling, 2005). This quality of ‘opening up’ 
applies not just to engagements with ‘decision-makers’, but also with 
other actors in the wider political debates in which decision making is 
set (Stirling, 2008b). 
Developed further in a number of distinctive ways for the purpose of 
the present project, the MCM process described in the following section 
enables the addressing of each of the six criteria discussed in the pre-
vious section for prospective appraisal of policy instrument mixes. 
First, MCM is strongly holistic in scope, in that appraisal criteria are 
freely developed by interviewees such as to address an unfettered array 
of policy considerations as they see them – without being driven or 
blinkered by the analyst’s own bias. Second, MCM adopts a balanced 
approach to a diversity of options, in that an initial set of core policy 
options are chosen by researchers for appraisal by all interviewees, such 
as to reflect a full range of axes of contrast in wider policy debates – with 
each interviewee free to add whatever additional options or changes of 
definition that they wish. 
Third, MCM explicitly permits a focus on portfolios of options rather 
than just individual options (Stirling, 1997; Yoshizawa et al., 2011) – a 
feature specifically applied in the present study. Fourth, the emphasis of 
MCM on attention to qualitative nuances in appraisal (as understood by 
different specialist perspectives), gives it a relatively high sensitivity to 
detailed conditionalities. Fifth, the priority placed in MCM to ‘putting the 
interviewee in the driving seat’ gives general confidence of its ability to 
engage in an unbiased way across a plurality of perspectives. Finally (in 
relation to the sixth criterion in the last section), MCM focuses 
throughout, not just on eliciting under each perspective a supposedly 
singular scalar representation of relative merit, but also on illuminating 
deep uncertainties. 
The above points suggest that MCM is a method well placed to 
address the demanding challenges of prospective policy appraisal as 
identified in the literature on policy instrument mixes. Indeed, to the 
extent that similar quality criteria apply, it might also be judged suitable 
for similar reasons, for retrospective policy evaluation. It is in testing the 
utility of a newly-developed version of this method in relation to these 
criteria, that a contribution to the practice of evaluation of innovation 
policy can be made at the same time as providing a rich empirical pic-
ture of relevant particularities across six European countries to inform 
the design of policy instruments to support AMR diagnostic innovation. 
Having identified a process and a method, the remaining part of this 
section focuses on some practical considerations to be addressed in the 
implementation of the method. 
3.2. Selection of core instruments for appraisal 
A preliminary question to address is which options should be 
included for appraisal by stakeholders. An immediate challenge is that 
an “ocean” of innovation policy instruments exists (Borrás and Edquist, 
2013) which can be classified in a number of ways (Steinmueller, 2010; 
Borrás and Edquist, 2013; Rogge and Reichardt, 2016). The first step is 
therefore to focus on an appropriate subset. There are various frame-
works that can inform such a selection. 
A commonly used three-fold categorisation distinguishes between (i) 
economic and financial instruments (ii) regulatory instruments and (iii) 
information (or soft) instruments – with these three being termed ‘car-
rots, sticks and sermons’ (Borrás and Edquist, 2013; Rogge and Reich-
ardt, 2016). 
Instruments can also be classified according to the functions of the 
innovation system, or the governance niche, that they target (Hekkert 
et al., 2007; Hopkins et al., 2019). In combination with the above, this 
approach rapidly generates dozens of potential categories of instrument 
(Borrás and Edquist, 2013). Moreover, it is immediately obvious that 
different facets of instrument design can further distinguish instruments 
that at first seem to fit within the same category; additionally, in-
struments may also perform more than one role (Hopkins et al., 2019), 
and so address more than one ‘box’ in a given matrix of instrument 
types. 
Yet more classificatory considerations include: whether an instru-
ment focuses on the supply-side or demand-side of a market (Borrás and 
Edquist, 2013; Rogge and Reichardt, 2016), often simplified as ‘tech-
nology push’ or ‘technology pull’ respectively; whether it addresses a 
(downstream) near market or upstream activity; and whether the actors 
driving the direction of innovation are public or private (Mazzucato, 
2013). 
As in any policy analysis, theoretical sophistication must at some 
point compromise with the practical necessity to engage with diverse 
stakeholders, who have limited analytical time to study the different 
options and finite bandwidth to address the cognitive demands of de-
cision analysis methods. This inevitably imposes constraints on the 
range of options that can be considered. Yet to address the quality 
criteria set out above, it is necessary to minimise artificial limits on the 
kinds of instruments included in appraisal. This dilemma can be 
reconciled by studying options at the level of ‘families’ of instruments – 
where the term family implies that specific included instruments share 
features such as their target and mechanism, while still being potentially 
variable in configurations of other characteristics. The identification of 
important ‘family’ characteristics allows multiple instruments to be 
appraised as a single policy option, so that comparisons can be directed 
at major shared features in modes of action with respect to an innovation 
system. Detailed appraisal by participants at the level of specific features 
of particular instruments can then be focused at a particular point in 
appraisal under a specific perspective. 
A further consideration in instrument definition, is not to select op-
tions that are merely theoretically possible, but to take seriously the 
history, context and politics (path dependency, agency and power) that 
have played a role in making certain options prominent in ongoing 
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debates. For example, on the topic of policy options for managing AMR, 
a considerable literature exists (summarised in the supplementary ma-
terials: Annex A) in which powerful actors strongly advocate particular 
policy approaches. Such established options need to be acknowledged, 
but are most rigorously appraised alongside alternatives. This study 
provides stakeholders with a diverse portfolio of policy options for 
appraisal, assembled following a comprehensive review of relevant 
policy literature (discussed further in Section 4.1). 
3.3. Customisation of instruments to fit context 
To address this task, stakeholders can be engaged in order to identify 
both the general options and their salient variations, as favoured (or not) 
in relation to contrasting appraisal criteria. Here, contrasting participant 
appraisals are ‘plural and conditional’ as individuals will be able to 
identify conditions under which an option can perform well or poorly 
(Stirling, 2006). The detailed positive and negative considerations that 
arise more generally can – despite crucial differences across contexts – 
offer insights for more localised design of policy options. 
In this international comparative study, the focus is on identifying 
policy options for national strategies to stimulate the diagnostic inno-
vation needed to tackle AMR. Given the diverse national settings and 
perspectives that any such analysis inevitably spans, a key task lies in 
addressing the general quality criteria set out above, asking which fea-
tures of policy options are variously favoured and disfavoured by 
different stakeholder groups under different conditions? It is in 
addressing this challenge, that the general point made above also ap-
plies, in that the qualitative reasons expressed as to why appraisals take 
the position they do on any given detail, are as important as the quan-
titative representations of relative orderings across options. 
In order for this demanding criterion to be respected, salient features 
of options need to be defined in a manner that provides consistency at 
the same time as allowing stakeholders to appraise under whatever is-
sues they consider to be most salient (with as little influence from the 
analyst as possible). What might count here as a ‘salient feature’ cannot 
comprehensively be anticipated ex ante, by the analyst, but will arise as 
an empirical result of the analysis itself. Yet this raises a further chal-
lenge, in that the greater the detail provided in advance by the analyst, 
the less generalizable appraisal can be across contexts and the higher the 
risk that interviewees will focus on minutia rather than broad principles. 
Stakeholders are therefore provided in MCM with a definition for each 
option that is only as detailed as can be retained in mind, for the purpose 
of a one- or two-hour intensive appraisal process (interview materials 
are provided in the supplementary materials: Annex B). Features of this 
description that come to the fore in different ways – like the envisaged 
mechanism, its intended target activities, the site of these in the inno-
vation system and the roles the instrument requires for the state or in-
dustry to play – can all then be noted insofar as they become relevant 
across different appraisals. Moreover, just as a stakeholder can define 
their own additional option, where they believe something of relevance 
has been missed, so too can they add whatever they might consider to be 
meaningful variations in definitions for those options that have been 
included. 
It is in these ways, that the definitions of options for appraisal in the 
MCM framework adopted in this study can address the demanding 
quality criteria described in Section 2 above. And it is on this basis, that 
the subsequent process can address the crucial additional challenges 
concerning variabilities across contexts, uncertainties about the future, 
ambiguities across perspectives and interactions between different in-
struments in a mix. In all these respects, the ability of MCM to compare 
appraisals under contrasting specialist perspectives, offers a greater 
basis for confidence in the resulting findings, than would be the case if 
the appraisal were (as is often otherwise the case) solely based on the 
understandings and interests of the analysts alone. 
3.4. Implications for the ‘instrument mix’ 
As was discussed in detail in Section 2 above, a crucial factor in 
appraisal is the attention paid not only to the conditionalities associated 
with specific instruments across contexts and perspectives, but also to 
the ways in which they may be expected to interact in a ‘policy mix’. It is 
partly for these reasons that the term ‘instrument mix’ is increasingly 
preferred in the literature to the more coarse-grain idea of a ‘policy mix’. 
But – as also discussed in relation to the quality criteria above – this 
presents an additional demanding challenge in appraisal. If attempts are 
made to address this in any encyclopaedic way, the sheer numbers of 
permutations across contexts, perspectives and instrument combina-
tions can quickly become prohibitive. Yet a more selective approach can 
leave analysis highly vulnerable to contingent design features or biases 
on the part of the analysts themselves. 
It is in this regard again, that the emphasis in MCM comes to the fore, 
of balanced attention across a diversity of specialist stakeholder per-
spectives. In ways described below, MCM attends in detail not only to 
quantitative orderings of relative merits, but also to detailed qualitative 
uncertainties, variabilities and justifications, as elicited from stake-
holders. To the extent that cross-dependencies between instruments 
come to light in these most salient respects, then the otherwise para-
lysing complexity is reduced. In the present exercise, analysts were 
especially attendant to this aspect throughout the appraisal interviews. 
At the end of each interview, interviewees were specifically asked to 
identify (in light of the detailed appraisal they had just undertaken) the 
most important negative and positive interactions between different 
instruments. It is on this basis, that the study discusses some of the more 
important kinds of interaction between instruments that come to light 
across different stakeholder perspectives. 
4. Method for participatory comparative appraisal 
Six quality criteria were derived in Section 2, to address the chal-
lenge highlighted in Borrás and Edquist (2013) for prospective appraisal 
of innovation policy instrument mixes. This section describes how the 
present novel application of MCM aims to respect these criteria, in 
appraising alternative policy options for promoting AMR diagnostic 
innovation across six European countries. 
MCM is an interactive method for exploring complex strategic and 
policy issues that is designed to capture different specialist stakeholder 
perspectives, and their respective rationales for the ‘best’ courses of 
action. The MCM process has been described in detail elsewhere (Stir-
ling and Mayer, 2001; Stirling et al., 2007; Bellamy et al., 2013) and so 
only an outline is presented here. The MCM process employed in this 
study is illustrated in Fig. 1, with the remainder of this section describing 
the process displayed. Prior to MCM interviews, (1) an appropriate array 
of relevant options needs to be defined, and (2) interviewees need to be 
selected, ensuring the inclusion of a relevant plurality of perspectives. At 
interview, (3) the standard MCM process allows individual interviewees 
to appraise options according to their chosen criteria, involving in turn 
(a) systematic development of appraisal criteria; (b) consideration of 
relevant uncertainties and conditionalities; (c) determination of relative 
subjective priorities to attach to different criteria; (d) attention to any 
relevant additional or varied options and finally (e) consideration for the 
validity of resulting overall orderings of options. 
This approach allows in-depth analysis of many different kinds of 
dimensions – including uncertainties in relation to individual options, 
issues or perspectives; ambiguities across different perspectives in all 
these regards; and contrasting rankings under divergent perspectives or 
across different national or other settings. A novel comparative analysis 
method is added here to the established MCM approach, drawing on and 
synthesising the quantitative (4a) and qualitative (4b) data from in-
terviews. Together these allow clearer insights into the selection and 
implementation of prospective policy instruments and instrument mix 
appraisal. 
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4.1. Selecting policy options 
To define a broad portfolio of policy options for appraisal at the MCM 
interviews, a two-stage process was followed. In the first stage an 
exhaustive list of policy instruments to promote innovation in the AMR 
field was identified. A literature review was undertaken based on 
sources published between 2004 and 2016. This included policy docu-
ments, and academic literature related to AMR and diagnostics. 
These were collected through a systematic search, which identified 
relevant source documents – namely those policy reports or academic 
articles that discuss diagnostic innovation and AMR, authored since 
2000. The search terms used to identify these documents were ‘antimi-
crobial resistance diagnostics’, ‘antibiotic resistance diagnostics’, and 
‘AMR diagnostics’. The results were augmented by AMR strategy doc-
uments from prominent bodies developing policy options (e.g. WHO, 
OECD, and EU). The aim was to collect a wide range of policy types 
focusing on a particular policy goal: The development and use of diag-
nostic tests to manage AMR. The search generated a set of 54 relevant 
source documents with the vast majority published within the last seven 
years (28 were published in the years 2015–2016, a further 20 between 
2010 and 2014, while just five pre-date 2010) (See supplementary 
materials: Annex A for the full list of references). This is in keeping with 
the authors’ understanding that AMR has been recognised only recently 
at the policy level as an emerging global challenge. 
The second stage involved classifying the instruments identified in 
stage one into families of policy instruments with the resulting options 
initially classified into ten categories, which themselves were classified 
as Science-Push models (three categories), Market-Pull models (seven 
categories) and an additional ‘other’ category. These were further 
reduced to six families of policy instruments, which address a broad 
range of needs across the innovation system, encompassing the different 
stages of the innovation process, various mechanisms of action and 
focusing on a range of actors. These six became the six policy options 
used in the MCM interviews with stakeholders. Table 1 describes how 
options were selected and provides a summary of their relative occur-
ance in the literature review (see Annex A). Table 2 sets out the final six 
options with definitions and details that differentiate them from each 
other, as shared with interviewees. 
4.2. MCM interviewees 
Different countries display contrasting needs and contexts with re-
gard to innovation policy for addressing AMR. In order to present results 
of relevance beyond particular national settings, this study therefore 
aims to span a diverse range of circumstances, whilst at the same time 
interrogating and reporting specific salient sites of investigation in their 
own terms. Among the explicit dimensions of this diversity, countries 
were selected in order to display variation in AMR prevalence (which 
correlates with antibiotic use), as well as in diagnostics market size. For 
AMR prevalence, although there is variation depending on the bacterial 
species and antimicrobial group, overall Germany and the Netherlands 
have low rates, while Italy and Greece have higher rates and the UK and 
Spain have more moderate rates (ECDC, 2017). In terms of economic 
size, Germany, Italy, Spain and the UK are amongst the largest European 
economies, offering large markets for diagnostics developers, with the 
Netherlands and Greece representing smaller economies offering 
smaller markets. Table 3 summarises some relevant contextual details of 
the six European countries studied. 
In order to assess policy options, interviewees were selected (i) to 
help analysts understand key country specificities and (ii) to span a di-
versity of stakeholder groups to bring understanding and experience 
from across each national health system. 
In each country, interviews were conducted with individuals from 
seven distinguishable stakeholder groups. These stakeholder groups 
were addressed in order to garner a salient plurality of perspectives on 
the diversity of circumstances noted above. Specific choices were based 
on understandings from prior research on diagnostics innovation (e.g. 
Hopkins and Nightingale, 2006). Groups included: primary care 
Fig. 1. The MCM process from interview preparation to analysis.  
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clinicians, secondary care clinicians, clinical laboratory scientists, 
pharmacists, industry executives, policy makers, and health technol-
ogy assessors, including health insurers/ payors (henceforth HTAs). A 
majority of the interviewees (36/47) were selected because of their 
individual involvement in national expert groups on AMR. 
While good coverage was achieved for the countries and stakeholder 
perspectives listed above; other identifiable kinds of perspective were 
not addressed in such balanced ways. For instance, much less than half 
of the sample were female (10/47); and the patient voice is missing from 
the study, as prominently engaged representatives of this group could 
only be identified and interviewed in one country. Table 4 summarises 
stakeholder participation in each country. Interviewees that did not 
have experience of national expert groups on AMR are indicated with a 
*. 
Each interview was conducted face-to-face by two team members in 
overlapping combinations to help ensure consistency in application of 
the interview protocol (FB/MH, FB/JMF, JC/FB, JC/MH and JC/MH +
SA ). Additional language translation was provided as needed in Greece, 
Italy and Spain, mainly by authors (SA for Greece, JMF for Spain) or 
exceptionally by local PhD students (see acknowledgements). Interviews 
lasted from 45 min to 2½ hours. All interviews were conducted between 
March 2017 and March 2018. 
The analysis presented here is based on 47 of 50 interviews under-
taken. MCM is a cognitively demanding approach, consequently, three 
interviewees were not able to provide full quantitative MCM assess-
ments at interview. As a result, quantitative and qualitative data from 
these interviews have been excluded from the analysis. Interviewees 
were free to appraise policy instruments in any order, thus reducing the 
scope for some instruments to be less carefully appraised due to undue 
influence from the protocol structure. 
A possible query that arises at this point, concerns how this array of 
47 interviews spanning seven identified perspectives across six coun-
tries, relates to received ideas in probabilistic sampling? It was already 
discussed in Section 2, that prevailing conditions of uncertainty and 
ambiguity (that the MCM process specifically seeks to address and 
reveal), render it difficult to justify any unitary objective aims or claims 
around ‘statistical representativeness’ (Stirling, 2010; O’Neill, 2001). In 
keeping with understandings that are well established both in quanti-
tative (Rothman et al., 2013) and in wider social research (Tracy, 2013) 
(Somekh and Lewin, 2005), such notions depend on prior confidence 
that the dimensionalities, definitions and partitionings are complete and 
definitive concerning what might constitute salient categories (such as 
‘parent populations’; ‘causal mechanisms’; or ‘frequency distributions’) 
(Kahneman and Tversky, 1974). In MCM (Stirling, 1997), as in other 
research methods, such as Q method (Stephenson, 1953), it is precisely 
these issues of framing and objectivity that are under scrutiny. So, sta-
tistical sampling methods are better understood as being dependant on 
(rather than prior to) the kinds of phenomena examined in MCM 
(Coburn et al., 2019). 
In these terms, the recruitment of perspectives for elicitation in MCM 
interviews might most appropriately be held to be subject to general 
disciplines of ‘scientific inference’ rather than ‘statistical inference’ 
(Mitchell, 1983). With each elicitation in its context also a unit of 
analysis in its own right (Small, 2009), the appropriate form of 
reasoning is in this regard more akin to ‘case study logic’ than to ‘sam-
pling logic’ (Yin, 2009). Relying more on ‘non-probabilistic methods’ 
(Parker et al., 1998), this raises considerations of ‘validity’ more than 
representativeness (Mitchell, 1983), ‘theoretical sampling’ more than 
statistical sampling (Silverman, 1989), and ‘potential for learning’ more 
than calculative generalisation (Stake, 1994). In interpreting MCM re-
sults as outcomes of deliberative policy appraisal involving inherently 
subjective framings (Davies et al., 2003) – qualities of ‘inclusiveness’ 
(O’Neill, 2001), ‘legitimacy’ (Chilvers, 2009) and ‘transparency’ (Stir-
ling, 2003) are more important than what has been termed the “false 
essentialism” of ‘statistical representativeness’ (Smith and Wales, 2000). 
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undertaken for the purpose of this study, might reasonably be judged to 
be an appropriate number in relation to the style and purpose of this 
analysis: mapping salient parameters of contrasting policy options and 
criteria, rather than seeking to generalise perspectives (Stephenson, 
1953). Either way, since what is under scrutiny in MCM are features of 
diverse framings in social discourse more than contingent psychologies, 
the most pertinent focus for statistical analysis would lie less in the 
number of participants, than in the many hundreds of data points (both 
scores and qualitative statements) associated with policy options and 
criteria. In any case, with the value of results lying in the learning they 
enable, the adequacy or otherwise of the particular elicited perspectives 
is better assessed in relation to the qualities of results (as set out in this 
Table 2 
Policy options organised by key features.  
Options Description Stage in 
pathway 
Mechanism Role of government / 
industry 
Actors of focus 
Enhance 
revenues 
Government encourages firms to participate in the 
diagnostics market by increasing financial rewards 
Downstream Pulls suppliers towards the 
market with incentives 
Government and 
private industry reliant 
Diagnostics firms 
Fund R&D Government encourages diagnostic innovation by 
providing researchers with more funding for R&D 
Upstream Pushes new technology 
towards the market 
Government reliant Public and private 
researchers, diagnostics 
firms 
Make pathways Government coordinates stakeholders to provide 
help for firms seeking to bring new tests to market 
Upstream Signals to suppliers the 
needs of the market 
Government and 




Government leads R&D and clinical testing to 
ensure optimal test use in their healthcare system 
Upstream / 
Downstream 
State provision of the 
required goods and 
services 
Government reliant Healthcare systems 
Incentivise use Healthcare providers create incentives and remove 
disincentives to encourage better use of tests 
Downstream Encourages demand to 






New tests are developed based on market demand 
and established international intellectual property 
protection regimes 
Downstream Pulls suppliers towards the 
market with incentives 
Private industry reliant Diagnostics firms  
Table 3 
Selected details for six European countries.  
Country Germany Greece Italy Netherlands Spain UK Source 
Population, 
total 








$3,307 (2012) €269 (2008) $2,017 (2012) $803 (2014) $1,461 (2008) $2,525 (2014) HiT 
reports* 
GDP per capita 
PPP 






















% of GDP 
11.3 9.6 9.2 12.9 8.5 9.1 HiT 
reports* 





insurance and 11% 
substitutive private 
health insurance. 
There is a mix of 
public and private 
funding.Public 
funding is from 
social insurance 
and private is 
















The (devolved) health 
system provides 
universal coverage 
funded from taxes and 
predominantly 




service, mainly funded 
through general taxation, 
with the remainder coming 
from private medical 







2 6 5 1 4 3 (Goossens 
et al., 2005 

















2 5 4 3 4 1 (Kelly et al., 
2016) 
*HiT reports:, Germany (Busse et al., 2014), Italy (Ferré et al., 2014), Netherlands (Kroneman et al., 2016), Spain (García-Armesto et al., 2010), UK (Cylus et al., 
2015). 
**by Penicillin non-susceptible S. pneumonia (%) (2001). 
***by total number of AMR diagnostic projects per country by priority topic funded at national level. 
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article but also in the supplementary materials: Annex C and D, intended 
to inform policy implementation), than in the quantities of inputs. 
4.3. The MCM interview process 
MCM software is used in this study to facilitate a structured 
interaction with stakeholders for the systematic appraisal of policy op-
tions at interview. Alternative options (i.e. different families of policy 
instruments) are presented to the interviewees as possible actions to 
achieve a ‘focal goal’, i.e. to promote the development and use of di-
agnostics to manage AMR through reduced antibiotic consumption. In 
MCM, participants are encouraged to think how different options may 
Table 4 
Interviewees by country, stakeholder group and experience.  
Stakeholder group Germany Greece Italy Netherlands Spain United Kingdom Total 
HTA 1 1 1 1* 1 1 6 
Industry 1 1 1* 1* 2 1 7 
Clinical lab scientist 1 1* 2 1 1* 1 7 
Pharmacist 1 1 1 1 1* 1 6 
Policy maker 2 (1*) 1 1 1 2 1 8 
Primary care clinician 1 1* 2 1 1* 1 7 
Secondary care clinician (infection) 1 1* 1 1 1 1 6 
Total 8 7 9 7 9 7 47 
*Interviewee not on a national AMR panel. 
Fig. 2. Analysis of quantitative data from MCM.  
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perform, taking into account complexities, uncertainties and ambigu-
ities, and allowing themselves to move away from any notionally single 
‘best answer’. MCM aims instead at ‘plural and conditional’ inputs to 
policy making (Stirling, 2006, 2008b, 2010). To do so, the interview 
process aims at unpacking these through different steps in the appraisal. 
After reviewing policy options, participants select a set of criteria that 
they think most closely affect the ability of each option to contribute to 
the focal goal (articulating conditionalities). The criteria selected by in-
terviewees in this study are available in the supplementary materials: 
Annex C. Under each criterion, interviewees express their appraisal of 
each policy option by assigning, an optimistic and a pessimistic score (to 
account for any uncertainty or conditionality, for example, related to 
mode of policy implementation), which is entailed with a discussion that 
supports these scores. After appraising each option from the perspective 
of each criterion, interviewees are able to compose an aggregated chart 
which accounts for the quantitative assessment of all the policy options 
under all criteria, with each criterion weighted by importance (see 
Fig. 1:(4a) Weighted ranks chart). The chart is shown to interviewees, 
who can iterate their appraisals as desired (together with supporting 
qualitative justifications) until they approve the final output of the 
discussion. At this stage, the interview moves on to elicit views on po-
tential complementarities or conflicts between policy options, to inform 
an understanding of appropriate mixes. 
4.4. Analysis of the MCM quantitative and qualitative data 
Thus far, it has been argued that the MCM process provides an 
approach that addresses the six criteria in Section 2, enabling the 
gathering of a rich array of quantitative and qualitative data. New 
methodological improvements to MCM that facilitate the analysis on 
both the qualitative (see Fig. 1(4b)) and quantitative front (see Fig. 2) 
are presented here as a way to enhance prospective appraisal of policy 
mixes. For reasons of space, the technicalities behind these improve-
ments are detailed separately (see MCM manual (Coburn et al., 2019)). 
Two new forms of data visualisation and analysis for MCM are 
applied here for the first time. These are what we refer to as the pairwise 
inclination chart and the merit order. As Fig. 2 indicates, the pairwise 
inclination chart uses the optimistic and pessimistic scores and the 
difference between them (i.e. the length of the bar) from the final ranks 
charts produced by each MCM interviewee to compare their appraisal of 
each possible pairing of the core policy options that they have appraised 
(i.e. six policy options yields 15 possible pairings for comparative pur-
poses from each interviewee). Subsequently, the outcomes from the 
analysis of all possible pairings are used to generate an overall merit 
order, distinguishing higher and lower performing options. In Fig. 3 
each pairwise comparison from each interviewee’s perspective is 
accorded equal focus (i.e. fairly engaging with a plurality of perspec-
tives). The figure represents the appraisals of all interviewees as a series 
of cells, each representing one interviewee’s assessment of the relative 
performance of one option over the other. The outcome is represented 
by the colour: superior performance of policy A is indicated in blue, and 
superiority of policy B is indicated in red. The degree of uncertainty 
expressed by interviewees is indicated through the degree of shading, 
with deeper shading indicating less uncertainty (for a full explanation of 
the chart and underlying calculations please refer to pages 105–111 in 
Coburn et al., 2019). Uncoloured (grey) cells show instances where 
there is no discernible inclination to be inferred from the optimistic and 
pessimistic scoring of either option in the pairwise comparison. The 
chart in its entirety provides a clear indication of the proportion of in-
terviewees more inclined to view one policy option as superior in per-
formance than another while also communicating the general 
uncertainties expressed by stakeholders. For example, in Fig. 3, the 
greater quantity of blue shading indicates that interviewees are more 
inclined towards policy A than policy B overall, while the light shading 
and grey cells show the uncertainties expressed by participants. 
Merit orders are derived by summing scores across participants for 
each policy option. These participants’ merit scores combine separation 
(between 0 and 1) with the direction of preference (+ or − sign). For a 
full description of how merit scores and merit orders are computed see 
MCM manual pp.105-111 (Coburn et al., 2019). They provide a syn-
thesis of pairwise comparisons, where policy options higher in the order 
have been appraised more positively overall. The separation between 
the options in the merit order indicates the margin by which an option 
can be said to be favoured compared to the adjacent policy options. 
Merit orders can be generated for all interviewees, to provide an overall 
view, or for subsets of interviewees to tease out differences in perspec-
tives, thus providing the ability to understand the role of these per-
spectives in determining the overall merit order. 
Fig. 3. Example of a pairwise inclination chart (47 interviewees) and how it is constructed using direction of preference and separation.  
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Yet, a deep understanding of context, conditionality and uncertainty 
cannot be obtained without the qualitative data accompanying quanti-
tative scores. In keeping with the aim to provide a fair level of 
engagement between all interviewees, the qualitative comments have 
also been analysed in a systematic way, pooling comments by policy 
option, thematically grouping similar issues (along with conditionality 
and expressions of uncertainty) and tallying these according to whether 
they were a part of optimistic or pessimistic appraisals (a detailed 
explanation of the extraction and grouping process can be found in the 
MCM manual pp. 94–104 (Coburn et al., 2019)). The qualitative data 
can be used to derive detailed insights into the expectations of in-
terviewees for particular policy options. For reasons of space, only those 
themes that recurred in more than 10% of interviews are displayed in 
the tables provided in Section 5. 
5. Empirical results 
Results are reported from 47 interviews across seven stakeholder 
groups in six countries, based on their appraisal of the same core set of 
policy options. The options are referred to by their names, e.g. ‘gov-
ernment provides’ and ‘incentivise use’, following the definitions set out 
in Table 2. 
This section addresses the second and third steps of the process for 
prospective policy instrument mixes set out by Borrás and Edquist 
(2013), namely the design and customisation of instruments and the 
design of instrument mixes. The section is divided into three sub-
sections. The first offers an aggregated view of the quantitative data in 
order to provide suitably-qualified indications of which options might 
be expected to perform most favourably across a range of European 
contexts. These are accompanied by analysis of pooled qualitative 
comments from all countries and stakeholder groups revealing 
commonly anticipated advantages and disadvantages for each policy 
option. Together, this analysis contributes a key basis for understanding 
how policy options can be optimised to address local needs and the 
conditions under which these are expected to perform well or poorly. In 
the second subsection, the disaggregation of appraisals by stakeholder 
group and country provides further insights concerning the varying 
suitabilities of different policy options to address AMR in particular 
national settings as seen from contrasting perspectives. In the third 
subsection, the potential is examined for policy options to be comple-
mentary or to conflict with each other. 
MCM interviewees are encouraged to add and appraise additional 
policy options where they feel further options ought to be considered 
alongside the core options. While additions cannot be appraised by other 
interviewees, these may offer further insights into the comprehensive-
ness of the core options used, as well as suggesting other possibilities for 
further enquiry. The additional options suggested by interviewees are 
listed in the supplementary materials: Annex C. 
5.1. Aggregated analysis 
Fig. 4 displays the results from the pairwise comparisons from all 
interviewees (i.e. 15 policy option pairing x 47 interviewees). In each 
panel (A-F) of Fig. 4 a given policy option is compared with all other 
policy options to reveal interviewees’ inclinations on the expected 
relative performance of each policy option. The key to interpreting the 
visualisation of data in Fig. 4 is provided in Fig. 3. 
As indicated by the shading conventions explained in the diagram 
key (in Fig. 3), Fig. 4’s Panel D shows that ‘incentivise use’ is generally 
more favourably appraised (intensity of blue shading on the left of the 
diagram) by more interviewees (numbers of cells), than other policy 
options (inclinations for which are indicated by red shading on the right 
of the diagram). The degree of ambiguity with which this remains the 
case is conveyed by considering the relative number of interviewees 
who display the opposite view (red) and by the intensity of shading in 
both (blue and red) views - (less strong relative orderings are indicated 
Fig. 4. Pairwise comparisons of policy options from all interviewees (see Fig. 3 
for an example showing how these charts were constructed using direction of 
preference and separation). 
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by less intense colours). It is quite clear across interviewees generally 
that they expect ‘incentivise use’ to perform better than ‘government 
provides’ and ‘protected markets’. Conversely, Panel C shows that 
‘government provides’ is the policy option that tends generally to 
perform least well when compared with all others. However, it is 
inherent to the complexities of appraisal reflected in MCM, that even 
this least favoured option has a relatively small number of supporters for 
whom it performs comparatively strongly, particularly in comparison to 
‘enhance revenues’ and ‘protected markets’. Specific reasons behind 
this are documented in the qualitative results. 
With ‘incentivise use’ tending to be the most favoured option overall, 
other highly favoured options are (in declining order of support) ‘fund 
R&D’ (shown in Panel B) and ‘make pathways’ (Panel E). An overall 
majority of interviewees tend to find these options more favourable than 
others. However, the relatively lighter shading (both of red and blue) 
indicates that there tends to be greater uncertainty across interviewees 
concerning the potential performance of ‘make pathways’. Finally, this 
pairwise comparison suggests that ‘enhance revenues’ (Panel A) and 
‘protected markets’ (Panel F) tend to be somewhat less favoured options. 
Those pairs of options that tend to elicit more divergent appraisals from 
interviewees can be seen to generate a greater proportion of stronger 
shading in both red and blue. 
Across all pairwise comparisons, a highly general relative ordering 
for all options can be expressed in the form of a merit order (see MCM 
manual (Coburn et al., 2019). Since the merit order averages across so 
many contexts, criteria and perspectives, it should be treated with great 
caution – with the aggregate picture complemented by the patterns 
evident in disaggregated quantitative and qualitative results (see Section 
5.2). However, simply as a broad heuristic the above general pattern is 
confirmed in Fig. 5, which quite clearly distinguishes between the 
overall favourability of a group of three ‘top’ (+) and three ‘bottom’ (-) 
policy options. Again, these results indicate by a considerable margin, 
that ‘incentivise use’ is the instrument that tends overall to perform best 
in the widest range of circumstances. This is followed by ‘fund R&D’ and 
‘make pathways’. The three options that tend to perform less well are 
‘protected markets’ and ‘enhance revenues’, which have broadly similar 
levels of support. Finally, ‘government provides’ is the option that tends 
to perform least well. 
Fig. 5. Merit order of six policy options (based on 47 interviewee appraisals).  
Table 5 
Optimistic and pessimistic qualitative comments about ’incentivise use’.   





Optimistic arguments    
1 Incentivising use will require guidelines, education, training and change management to change 
behaviours and culture and this will increase awareness 
DE(7) GR(3) IT(3) SP(6) UK 
(4) 
NL(0) 
PC(4) P(4) I(4) PM(5) 23 
2 Incentivising use is cost effective. It is not very expensive and appropriate use of diagnostic tests and 
antibiotics can save money. 
DE(5) GR(3) IT(3) NL(3) SP 
(4) UK(4) 
PC(3) SC(3) P(4) PM(5) 
HTA(3) 
22 
3 Incentivising use encourages optimal test use and appropriate use of antibiotics, improves patient 
outcomes and reduces AMR 
NL(5)SP(5)DE(5) PC(3) P(4) CLS(3) I(3) 
PM(4) 
20 
4 There is a need to change the reimbursement system as antibiotics are cheaper than diagnostics. 






4 Incentivising use is possible and acceptable UK(5) PM(4) HTA(3) 
PC(0) I(0) 
11 





Pessimistic arguments    







2 There are no funds available and / or it may not be cost effective due to the pricing of diagnostics UK(4) CLS(3) 12 
3 This is difficult to implement in terms of coordinating different stakeholders with different interests at 




4 This is pessimistic if it is not supported by an implementation strategy including communication, 
guidelines and training 
SP(4) 
GR(0) UK(0)  
9 
PC (Primary care), SC (Secondary care), P (Pharmacist), CLS (Clinical lab scientist), I(Industry), HTA, PM (Policy maker). 
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Table 6 
Optimistic and pessimistic qualitative comments about ’fund R&D’.   




Optimistic arguments    
1 Collaboration between public and private are important DE(4) IT(3) SP(3) HTA(4) PM(4) 
P(0) 
15 
1 Particularly clinical utility and cost effectiveness research to provide evidence DE(4) SP(3) UK(4) PC(3) I(3) 15 










5 Funding R&D generates knowledge and encourages diagnostic innovation and development of novel tests DE(3) NL(4) 
IT(0) UK(0) 
HTA(0) 10 
6 Funding R&D is cost effective NL(7) UK(7) 
DE(0) GR(0) IT(0) 
CLS(0) 8  
Pessimistic arguments    
1 Funding R&D may not be successful NL(3) SP(3) 
GR(0) IT(0) 
HTA(0) 9 
2 There is not enough money available for funding R&D DE(0) UK(0) HTA(0) P(0) 7 
2 There may be problems with bureaucracy NL(0) PC(0) I(0) 7 
2 If funding does not include clinical validation DE(4) UK(3) 
GR(0) IT(0) NL(0) SP(0) 
PC(0) 7 
PC (Primary care), SC (Secondary care), P (Pharmacist), CLS (Clinical lab scientist), I(Industry), HTA, PM (Policy maker). 
Table 7 
Optimistic and pessimistic qualitative comments about ’make pathways’.   




Optimistic arguments    
1 Making pathways could coordinate different stakeholders and create consensus between the 
stakeholders about what is needed 
DE(6) GR(6) IT(4) NL(3) SP 
(5) UK(3) 
PC(3) P(5) CLS(4) I(5) 
PM(6) 
27 







2 Pathways are already being made. It is acceptable and feasible. DE(3) IT(3) UK(4) CLS(3) PM(4) HTA(3) 14 





5 Clear evidence-based guidelines are needed and making pathways also helps to clarify what kind 
of evidence is needed. 
DE(3) NL(3) 
GR(0) SP(0) UK(0) 
CLS(0) 7  
Pessimistic arguments    
1 Coordinating a complex system with multiple stakeholders is difficult GR(4) IT(6) NL(5) SP(4) PC(3) SC(3) P(4) I(4) PM 
(4) 
22 
2 This option is not needed as adequate pathways already exist GR(0) HTA(0) 8 
3 Making pathways is not cost effective, particularly if there is no impact GR(0) IT(0) NL(0) P(0) CLS(0) I(0) 6 
PC (Primary care), SC (Secondary care), P (Pharmacist), CLS (Clinical lab scientist), I(Industry), HTA, PM (Policy maker). 
Table 8 
Optimistic and pessimistic qualitative comments about ’enhance revenues’.   




Optimistic arguments    
1 Enhancing revenues encourages more companies to innovate and develop diagnostic tests DE(3) NL(5) SP(3) 
UK(3) 









3 Collaboration and communication between public and private are important IT(4) 
DE(0) SP(0) 
SC(0) PM(0) 8  
Pessimistic arguments    
1 Enhancing revenues is expensive and not cost effective NL(4) SP(5) UK(6) 
DE(0) IT(0) 
SC(4) I(3) PM(4) 
CLS(0) 
17 
2 Government cannot / should not provide additional funding to companies SP(3) PC(3) CLS(3) 13 
3 There is a risk that the focus for firms is on maximising profits and not on societal benefit DE(3) GR(4) NL(3) 




4 There are uncertainties about patient needs and resistance, quality of evidence and product, clinical utility, 






PC (Primary care), SC (Secondary care), P (Pharmacist), CLS (Clinical lab scientist), I(Industry), HTA, PM (Policy maker). 
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5.2. Analysis by policy option 
This overall ordering of options can be contextualised by the dis-
aggregated picture for different settings and perspectives (e.g. Figs. 6 
and 7 discussed in the following section) as well as the qualitative re-
sponses that interviewees were asked to provide as commentary during 
the course of their appraisals of the different policy instruments. This 
latter rich body of information arises from each interviewee being 
frequently prompted to give reasons, caveats or other comments con-
cerning different detailed aspects of their appraisals. These qualitative 
responses are discussed in the following section. 
Key features of the corpus of qualitative responses gathered from the 
47 interviewees are summarised in Tables 5–10. These may help inform 
policy makers of many considerations helpful for the design of policy 
instruments or their modes of implementation. For example, the tables 
indicate which kinds of more commonly anticipatable problems might 
arise in different cases and suggest specific options that may be more or 
less suited in different contexts. 
The MCM process cues each interviewee to make as many comments 
per instrument as they think is appropriate, hence the numbers of re-
sponses recorded in the tables varies (although each interviewee’s 
contributions are counted towards each theme only once). The number 
of occurrences indicated in the tables refers to how many of the 47 in-
terviewees made comments that fall within a given theme. Given that 
each perspective (country or stakeholder group) is represented by be-
tween 6 and 9 independently selected interviewees, where three or more 
from a single perspective contributed to the same theme this is high-
lighted in the relevant table as a notable replication of interviewee 
findings. Similarly, where no interviewee from a given perspective 
commented on a theme, this is also indicated as notable (although again, 
due to space, not all of these details can be discussed in this section). 
Table 5 shows that almost half of interviewees (23/47) thought that 
change management, new guidelines and/or communication strategies 
would be needed to ensure successful implementation of the most fav-
oured option, ‘incentivise use’. Interviewees often suggested that this 
policy option had some form of financial merit (21/47) and they 
explicitly indicated it could be beneficial for patients and/or reduce 
AMR (20/47). There was less consensus regarding the pessimistic views 
expressed, but a frequent concern was that the incentive selected might 
not be effective (13/47), with UK interviewees strongly contributing to 
this point. Another concern was that a sufficiently motivational incen-
tive might not be affordable or cost effective (12/47). Again, this was 
particularly a concern held by a high proportion of interviewees in the 
UK and in the clinical lab scientist stakeholder subset. A concern that 
coordination issues might not be suitably addressed was also raised (9/ 
47), being highlighted most often by interviewees in Spain, and most 
often by the industry stakeholder subset. 
Table 6 shows the most frequent interviewee responses to the second 
most favoured policy instrument, ‘fund R&D’. This was often expected to 
work best if it could encourage public-private collaborations (15/47) or 
when the focus was on providing evidence of the clinical utility or cost 
effectiveness of tests (15/47). Interviewees frequently said this was an 
Table 9 
Optimistic and pessimistic qualitative comments about ’protected markets’.   





Optimistic arguments    
1 Protecting markets encourages diagnostic innovation based on needs by making the diagnostics market 
profitable and this improves patient management 
DE(5) IT(4) NL(4) SP(4) PC(4) P(3) CLS(4) 
PM(5) 
20 
2 Protecting markets does not cost much GR(3) UK(3) 
DE(0) NL(0) SP(0) 
CLS(0) I(0) 7 
3 Protecting markets is necessary but not sufficient on its own. It is a prerequisite. DE(0) NL(0) SP(0) PC(0) I(0) HTA(0) 5 
3 This is already internationally established and used everywhere in the world. The rules are already there, the 
principles are already there. 
IT(0) UK(0) P(0) CLS(0) 5  
Pessimistic arguments    
1 Protecting markets costs money and doesn’t add much to the policy portfolio.This could mean too much money 
being paid to industry. 
IT(3) UK(4) SC(3) PM(6) 
CLS(0) I(0) 
12 
2 Protecting markets is not working well and it is not going to work well UK(6) 
DE(0) GR(0) IT(0) NL(0) 
UK(0) 
SC(0) 7 
2 Protecting markets is about money and not sustainability, improving evidence, patient access, or preserving 
effectiveness 
IT(4) 
DE(0) GR(0) UK(0) 
CLS(0) 7 
PC (Primary care), SC (Secondary care), P (Pharmacist), CLS (Clinical lab scientist), I(Industry), HTA, PM (Policy maker). 
Table 10 
Optimistic and pessimistic qualitative comments about ’government provides’.   




Optimistic arguments    
1 Government provision could be cost effective if governments are in control of the whole process and can take 
the lead on pricing and reimbursement 
GR(3) UK(3)NL(0) CLS(0) 10 
2 This could happen if there is a national crisis, a change in political will, a market failure or for particular 
cases 
UK(4)GR(0) IT(0) PM(4)P(0) HTA(0) 8 
3 Optimistic if the government leads on improving access to laboratories and bacteria, and on improving the 
quality of clinical testing and evidence 
IT(0) SP(0) PC(0) SC(0) 7  
Pessimistic arguments    
1 Government provision would be prohibitively expensive, it could be a waste of money and it is not likely to 
be cost effective 
IT(3) NL(4) SP(3) UK(5) PC(3) SC(3) PM(7) 
CLS(0) 
19 
2 Government does not have the capacity or capabilities to do this DE(3) SP(4) UK(3)IT(0) SC(3) PM(4) 13 
3 Government provision would be slow DE(3)GR(0) SP(0) PC(0) 8 
4 There is not the infrastructure to do government provision IT(3)DE(0) NL(0) PM(3)P(0) 8 
5 Government provision will not work.It is not a good option. DE(3) UK(3)GR(0) IT 
(0) NL(0) 
PC(0) SC(0) 8 
PC (Primary care), SC (Secondary care), P (Pharmacist), CLS (Clinical lab scientist), I(Industry), HTA, PM (Policy maker). 
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acceptable (14/47) and feasible (12/47) policy option. Pessimistically, 
some were concerned that R&D funding schemes were not always suc-
cessful (9/47), a point raised mainly in the Netherlands and Spain. 
Affordability was also sometimes a concern (7/47). Other concerns were 
that R&D funding schemes could be too bureaucratic (7/47). Finally, 
there was concern raised by some UK and German interviewees that 
R&D funding might not focus sufficiently on the clinical validation of 
diagnostic testing (7/47). 
Table 7 shows that ‘make pathways’ was seen as a useful way to 
coordinate stakeholders and reach consensus on the tests required to 
manage AMR (27/47). It was often expected to be cost-effective or at 
least not too expensive (14/47) and was frequently seen as an acceptable 
or feasible option (14/47). However, many said that stakeholder coor-
dination was difficult in complex healthcare systems (22/47). This was 
raised most often as a concern by interviewees in Italy, the Netherlands, 
Spain and Greece, and it was also particularly a concern for policy 
makers, industry, and pharmacists. Some thought that this instrument 
would not be cost-effective (6/47) or that sufficient pathways were 
already in place and no further actions of this kind were needed (8/47). 
Table 8 shows that arguments in favour of ‘enhance revenues’ 
included that it could encourage firms to develop innovative tests (17/ 
47). This was seen as a feasible option by at least some interviewees 
across country subsets (12/47). Some viewed ‘enhance revenues’ as 
more favourable when undertaken with collaboration and/or commu-
nication between public and private sectors (8/47), with this view 
mentioned most often by interviewees in Italy. However, there were 
frequent concerns that this instrument would be expensive or not cost 
effective (17/47). This concern was held more often by interviewees in 
the UK, Netherlands and Spain, and particularly by policy makers, in-
dustry and secondary care clinicians. Interviewees often suggested that 
firms should not be offered additional money to develop tests (13/47). 
This was most mentioned by interviewees in Spain, by primary care 
clinicians and by clinical lab scientists. Concerns that ‘enhance reve-
nues’ could lead to profiteering without delivering societal benefit (10/ 
47) were raised by a high proportion of interviewees in Germany, Greece 
and the Netherlands, and particularly by policy makers and secondary 
care clinicians. 
The ‘protected markets’ option provided interviewees with an op-
portunity to discuss the status quo regarding the current provision of 
intellectual property protection as an incentive to bring diagnostic tests 
to market. As Table 9 shows, this was seen to be beneficial by many 
interviewees as it encourages innovation (20/47) and some interviewees 
from Greece, Germany and the UK viewed this as a relatively inexpen-
sive policy (7/47). Protecting markets was seen by some as necessary, 
but not sufficient to address the challenge of diagnostic innovation to 
manage AMR (5/47). A few also noted that it was already well estab-
lished (5/47). Some saw ‘protected markets’ as too costly for the benefits 
it provided (12/47), with this view being most often mentioned in the 
UK and Italy, and by policy makers and secondary care clinicians. Some 
commented that ‘protected markets’ was not working well in the context 
of diagnostics (7/47), with this final point being mentioned particularly 
frequently by interviewees in the UK. 
Table 10 shows there was little consensus on benefits for the least 
favoured option, ‘government provides’. However, some interviewees 
did suggest that having control over the whole diagnostic innovation 
process, including pricing, could aid cost-effectiveness (10/47). This 
option was considered more suitable for situations of national crisis (8/ 
47). Some also saw potential benefits if access to testing, suitable evi-
dence and/or test quality improved under this policy (7/47), and this 
was highlighted most often in the UK. There was more agreement on the 
Fig. 6. Merit order by country-level perspectives of interviewees.  
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pessimistic appraisals. ‘Government provides’ was viewed as potentially 
very costly and unlikely to be cost effective (19/47), especially by policy 
makers. There were also concerns from some interviewees in Germany, 
Spain and the UK, and also particularly from policy makers, that the 
public sector did not have the capability or capacity to be able to deliver 
this option (13/47). 
5.3. Analysis by country and stakeholder groups 
The previous section has highlighted the overall results to under-
stand whether and to what extent there is convergence or disagreement 
between all participants on the favourability of the policy options under 
appraisal. This section reports the breakdown by country and stake-
holder groups, to identify any notable differences in appraisal. These 
provide additional information about context because policies need to 
take into account variation, conditionalities and uncertainties linked to 
specific settings. 
Starting with the disaggregated country subsets, Fig. 6 shows that 
there is no consensus across subgroups as to the preferred policy option, 
as none share the same ordering. The country subsets reveal that broadly 
speaking, ‘incentivise use’ features at the top of most country subsets’ 
merit orders, with the exception of the Greek subset. According to the 
merit order, collectively Greek interviewees in this exercise ranked 
‘protected markets’ highest. Their qualitative comments highlighted 
that it was seen as being a cost effective option, compared to ‘incentivise 
use,’ which was seen as difficult to implement due to the need for co-
ordination between stakeholders at different levels (see Table 5). ‘Make 
pathways’ and ‘Fund R&D’ also featured in the top three preferred op-
tions across all country subgroups, and therefore may be applicable 
across contexts. Finally, ‘protected markets’ and ‘government provides’ 
do not feature in a consistent manner across country subsets. For 
instance, a higher proportion of interviewees from Greece and the 
Netherlands ranked ‘protected markets’ more favourably compared to 
those in other subgroups. While interviewees from most countries are 
particularly pessimistic about ‘government provides’, a higher propor-
tion of interviewees from the UK and Spain seem to have a more 
accepting view of these options. 
The merit order for the Greek subset is particularly notable for its 
differences with other country subgroups. Here, ‘protected markets’ is 
unusually favoured (recall in Table 5 that 3/7 Greek interviewees saw 
this as an affordable option), and ‘incentivise use’ is relatively dis-
favoured, (recall that 3/7 Greek interviewees envisaged the coordina-
tion of stakeholders at different levels as a difficulty – see Table 5). 
Furthermore, options are less distinctly separated in the merit order for 
Greece than in other countries. A potential explanation for both of these 
observations centres on the high level of political uncertainty that pro-
vided the setting for Greece at the time of the interviews. The Greek 
government’s capacity for AMR policy making was severely constrained 
due to externally imposed budget controls by the Troika (the Interna-
tional Monetary Fund (IMF), EU and the World Bank) (Mavroudeas, 
2017; Mavridis, 2018). As a result Greek health expenditure, which had 
been higher than average for the EU, was cut by 32% following the 
Troika’s intervention (OECD, 2016a) . In this context, the upholding of 
an established international intellectual property regime supporting 
‘protected markets’ for innovative diagnostics was relatively inexpen-
sive. By contrast, policies dependent on new national expenditure such 
as ‘fund R&D’ or ‘incentivise use’ were seen as less fitting. One inter-
viewee said “we don’t have the money to do R&D here in Greece” and 
another said that if the government “take a measure which is not very 
good for the IMF, the IMF pressure them to take it back”. 
A higher proportion of interviewees in the Netherlands subset also 
provided a relatively high ranking for ‘protected markets’ compared to 
other subgroups, as it was seen as necessary to make the diagnostic 
market profitable. At the same time, due to effective practice seemingly 
Fig. 7. Merit order by stakeholder group.  
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already in place (recall the Netherlands has low levels of AMR – see 
Table 3) initiatives such as ‘make pathways’ were seen as less relevant 
than elsewhere, and most of the interviewees from the Netherlands 
suggested that the required coordination across the system for this op-
tion would be complex and difficult (see Table 7). Indeed, this is a point 
also often raised by interviewees in Italy, Spain and Greece for ‘make 
pathways’. 
Fig. 7 displays the disaggregated merit orders to explore the varia-
tion between stakeholder subsets. Once again it is observed that no two 
groups share the same merit order, nor does any perspective’s ordering 
entirely agree with the general merit order obtained from aggregation of 
all interviewee data. 
The top-three options generally favoured in the overall aggregation 
were less commonly placed together in the stakeholder perspective 
analysis, thus indicating that stakeholder differences may be relevant to 
consider when forming policies. Only in two groups (policy makers and 
primary care clinicians) did ‘incentivise use’, ‘fund R&D’ and ‘make 
pathways’ form the more favoured top three options. There was less 
consensus over the most favoured option, with only 2/7 stakeholder 
subsets clearly expecting ‘incentivise use’ to perform best, although the 
option was rated in the top 3 for the remaining 4/7 stakeholder subsets. 
Support was notably stronger from interviewees in the diagnostics in-
dustry, a high proportion of whom favoured ‘incentivise use’ much more 
than all other options (recall in Table 5, 3/7 industry interviewees 
highlighted this could increase revenues and encourage diagnostic 
development). Pharmacists also often identified ‘incentivise use’ as the 
option they expected to perform best, for similar reasons to industry 
representatives. Interviewees in the clinical lab scientists and HTA 
subsets favoured both ‘fund R&D’ and ‘incentivise use’ (the difference in 
ratings between the two policy options does not enable a strict conclu-
sion). The merit orders indicate a high proportion of interviewees in the 
policy maker and primary care clinician subsets expect that both 
‘incentivise use’ and ‘make pathways’ would perform best. Secondary 
care clinicians were the least favourably inclined towards ‘incentivise 
use’ although it still appears in their top three options. 
The evaluation of ‘protected markets’ varied markedly across 
stakeholder subsets. There was more agreement on the relatively low 
expectations for ‘enhance revenues’, ranked fifth or below by most 
groups (4/7) except for more favourable rankings by industry repre-
sentatives and policy makers (who placed it third and fourth respec-
tively). ‘Government provides’ was often appraised among the least 
favourable options (4/7), although HTAs favoured it more highly, 
placing it in third place well above ‘enhance revenues’. 
Overall, the comparison of merit orders across perspectives has 
revealed that the aggregated merit order hides some notable differences 
in perspective between stakeholder and country interviewee subsets. 
However, the results also reinforce the aggregated merit order in some 
respects too. It is particularly clear that from most country and most 
stakeholder subsets’ perspectives, ‘incentivise use’ is expected to 
perform well. This is notable because this policy option is not the most 
prominent in the review of policy literature (see Annex A). Meanwhile 
‘enhance revenues’ which enjoys more prominent support in the policy 
literature does not perform particularly well in most country subsets and 
the only stakeholder subsets particularly favouring this are policy 
makers and industry. Less surprisingly, an option that is perhaps more 
radical, and less discussed in the policy literature, ‘government pro-
vides’, is the most widely expected to perform poorly. 
5.4. Policy mixes 
After appraising each option in turn, interviewees were invited to 
discuss how they would configure an instrument mix from the options 
that they had appraised. A majority of interviewees (35/47) provided 
views on possible policy mixes. Table 11 records the number of in-
terviewees identifying conflicts or tensions (shown in the lower triangle) 
or complementarities and synergies (shown in the upper triangle) for all 
combinations of policy instrument pairs. 
Table 11 shows that those options most favoured in the merit order 
tend also to be those viewed as being most strongly complementary 
with each other in a prospective policy mix. Furthermore ‘incentivise 
use’, the most favoured option in the merit order, is also viewed as the 
most complementary option overall and identified as most comple-
mentary to ‘make pathways’ and ‘fund R&D’ which together make up 
the other options in the top three favoured policies from the merit 
order. The interviewee quotes below illustrate some of the reasoning 
accompanying suggestions these were complementary options. The 
quotes demonstrate that interviewees recognised these three policies 
could have an impact in different parts of the innovation system, and 
why they thought these policies would work better in combination 
than individually. 
“I think ‘making pathways’, ‘incentivise use’, and ‘fund R&D’ [are 
complementary] … because I think with the pathways you identify 
the gaps, you can brainstorm about possible solutions, by ‘funding 
R&D’ you get to those solutions, and with ‘incentivise use’, you get 
better implementation.” - Secondary care clinician, the Netherlands. 
Table 11 
Complementarity and conflict between policy options as expressed by 35/47 interviewees.  
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“It’s a combination, I wouldn’t stick with one policy. It’s got to be 
about ‘incentivise use’ and the patient pathways, if you like if you 
have NICE [the UK’s main health technology assessment agency] 
guidance with teeth, that would be a similar thing, so I think those 
two combined, so you’ve got to have a new policy or a new pathway 
and then it’s got to be adopted because my worry is that we have 
policies that say let’s do this and then no-one does it. There’s the 
execution phase. I think you’d have to combine two. I think ‘make 
pathways’, I think they already exist, the ‘funding R&D’ is a great 
thing to do where there’s a gap if the commercial market sees no 
value in developing it, that’s where that makes perfect sense.” - In-
dustry executive, the UK. 
“In simple words ‘incentivise use’ and ‘enhance revenues’, these are 
policy options that define the aim and create the motivation, and 
‘funding R&D’ and ‘making pathways’ gives the companies tools or 
support to reach the aim so you should, or one should, combine 
either of these two (‘incentivise use’ and ‘enhance revenues’) with 
either of these two (‘fund R&D’ and ‘make pathways’).” - HTA ex-
ecutive, Germany. 
“’Fund R&D’ is necessary but not sufficient so there needs to be some 
money in the short term going into that space so you can kick start 
the pipeline, that you can encourage some immediate off the mark 
investment in these new technologies. Beyond that I think focusing 
on ‘incentivisation of use’, on mechanisms to disrupt the system and 
to directly encourage and ‘incentivise the use’ of these products is the 
main way to do it” - Policy maker, UK. 
Less than a quarter of those providing views on the policy mix (8/35) 
identified policies as being in conflicts or tension with each other. 
Almost all of these tensions were associated with ‘protected markets’ 
which was identified as being in tension with ‘enhance revenues’, 
‘government provides’ or ‘incentivise use’. 
6. Discussion and conclusion 
The rise of infectious diseases resistant to available medicines con-
stitutes a major global challenge. This study provides detailed analysis of 
stakeholders’ views with the aim of informing the development of policy 
mixes to stimulate diagnostic innovation in order to address AMR. In 
line with previous research, this study has sought to systematically 
appraise policy instrument mixes as seen under a diverse range of 
specialist stakeholder perspectives. Particular attention has been paid 
here to the conditionalities attending the fit between particular policy 
options and specific national settings as well as to uncertainties within, 
and ambiguities across, perspectives and to issues bearing on the design 
of policy mixes comprising a diversity of individual instruments (Borrás 
and Edquist, 2013). 
6.1. Contribution to general prospective appraisal of innovation 
instrument mixes 
The study has demonstrated a newly enhanced form of MCM in order 
to capture quantitative and qualitative appraisal by all interviewees, 
which could be applied to support systematic appraisals in innovation 
policy. By focusing on systematic and comprehensive pairwise analysis 
of policy options, it has been possible to combine representation of 
ambiguities in stakeholders’ relative degree of pessimism and optimism 
for each option in appraisal, together with the uncertainties they 
perceive about the future performance of individual options. This novel 
method builds on different traditions in decision analysis in order to 
illuminate key factors underpinning stakeholders’ inclinations to favour 
some options over others when considering a portfolio of options. 
Without disregarding crucial aspects of variance and uncertainty, the 
method helps to inform policy making by deriving a picture of overall 
merit orders. 
Although this article is primarily focused on the design of policy 
making concerning diagnostic innovation to address AMR, the same 
broad approach might reasonably be expected to hold relevance for 
wider applications in policy appraisal, innovation foresight, technology 
assessment and research evaluation. Whilst individual policy in-
struments are often subject to evaluation, this is rarely as balanced 
across diverse options and perspectives, nor as attentive as here, to 
uncertainties and ambiguities, nor (crucially) as explicit in the consid-
eration of the design of instrument mixes. The hybrid approach 
described here may help facilitate wider efforts to integrate the con-
trasting qualities of quantitative and qualitative approaches. 
6.2. The design of policy instrument mixes to stimulate diagnostic 
innovation against AMR 
6.2.1. Findings on ‘common ground’ and differences 
The emerging threat to global health from AMR has motivated an 
international response with a surge of policy reports and research 
studies published in recent years. These express a widespread view that 
systemic responses to AMR are required by national innovation systems, 
including specific support for diagnostic innovation. These documents 
have variously advocated a range of different policy options, although 
not always with rigorous explanations of how the favoured options were 
identified or on what grounds. Often neglected is how policy needs vary 
between countries and change over time. 
Focusing on six European countries, this study provides a systematic, 
rigorous and transparent approach to appraising a wide range of policy 
options, including those most prominent in the extant literature, as well 
as some less frequently mentioned. Among the many conditionalities 
this analysis permits to be interrogated, are the particular circumstances 
of each of the six different countries addressed. It is in respect of asso-
ciated variations, for instance in the maturity of the diagnostics inno-
vation system or the extent of the national AMR threat, that analytical 
disaggregation may be necessary to reveal the fit of particular options 
with anticipated needs in a given setting. Also highly relevant for the 
design of options, are the contrasting views on favoured policy options 
displayed under different stakeholder perspectives. 
Yet despite the care taken to elicit and assimilate variations in ap-
praisals from diverse positions, a key feature that emerges in this anal-
ysis is a relative consistency in respect of the options revealed to be most 
and least favoured. That such a finding is resolvable (in a suitably 
qualified way), is all the more salient for being the result of an approach 
that is so dedicated to illuminating diversity in so many different ways. 
Those features most broadly agreed in these merit orderings suggests 
strongest interviewee support for the option to ‘incentivise use’ of 
clinical diagnostic tests, with weakest interviewee support for the option 
where ‘government provides’ diagnostic innovations directly without 
reliance on commercial actors. An overall tendency to most favour 
‘incentivise use’ was evident across subsets of interviewees for five of the 
six countries studied (the exception being Greece). For interviewee 
subsets from Germany, Spain, the UK and Italy, common ground also 
emerged around relatively favourable appraisals of ‘fund R&D’ and 
‘make pathways’ with these joining ‘incentivise use’ as the top three 
most consistently favoured policies. In these same four interviewee 
subsets, ‘enhance revenues’ and ‘protected markets’ join ‘government 
provides’ as the three options that tend to be least favoured overall. 
However, this broad-brush picture is under-laid by a number of key 
contextual qualifications. That there is evidently no one-size-fits-all so-
lution, makes these nuances especially important in determining the 
appropriate mixes for particular national settings. For instance, this 
point was particularly clear from the results obtained from Dutch and 
Greek interviewees. That the ‘make pathways’ option was relatively less 
strongly favoured in comparative terms in the Dutch subset, related to 
the comparatively well-supported healthcare system and relatively low 
incidence of AMR in this country. For a higher proportion of the Greek 
interviewees, by contrast, there was less confidence in implementing 
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policies requiring new national expenditure (in a country still recovering 
from the financial crisis at the time interview data was collected (Har-
douvelis et al., 2018; Mavridis, 2018)). However, there was compara-
tively greater confidence in the Greek conext in policy options rooted in 
external frameworks, such as the EU intellectual property regime that is 
central to providing ‘protected markets’ for innovative products. 
Also important in these relatively broad terms is the result that the 
three policy options identified above as more highly favoured across 
diverse stakeholders’ views on an individual basis, also tended to come 
most positively to the fore in interviewees’ appraisals of their potential 
to be complementary with each other (rather than in tension) when 
included together as parallel policy instruments in the same mix. Despite 
the important diversity across different settings and perspectives, a 
consistent picture across a high proportion of the interviewees from 
Germany, Italy, Spain and the UK was to favour a combination of 
‘incentivise use’ with ‘fund R&D’, as well as ‘incentivise use’ and ‘make 
pathways’. It is notable that the counterparts to ‘incentives use’ in each 
respect (‘fund R&D’ and ‘make pathways’) also independently featured 
as the next most compatible pairing for mixes. The findings on in-
terviewees’ views regarding instrument mixes are all the more persua-
sive for being based on data collected at the close of the interviews, 
outside of the MCM process used to appraise individual instruments. 
6.2.2. Differences between stakeholder perspectives 
It is a particular facility of MCM that disaggregated pictures can 
easily be derived for contrastingly-defined groupings of perspectives. 
Distinguishing for this purpose between appraisals undertaken by in-
terviewees in subsets identified as industry executives, pharmacists, 
primary care clinicians, and policy makers, a picture emerges, that the 
‘incentivise use’ option tended to be highly favoured, with the ‘make 
pathways’ option ranking second. Clinical lab scientists and HTA ex-
perts, by contrast, tended to appraise ‘fund R&D’ most favourably, 
closely followed by ‘incentivise use’. Secondary care clinicians tended to 
be more favourable towards ‘fund R&D’, closely followed by ‘protected 
markets’. 
Lower down the merit orders there were more marked variations 
between groups. This is perhaps not unexpected given the different in-
terests in play – with different parts of the innovation system being 
better known to some stakeholder groups than others and different 
policy instruments bringing resources to different parts of the innova-
tion system. These differences accepted, it tended notably to be 
‘incentivise use’, ‘fund R&D’ and ‘make pathways’ that featured most 
frequently as the highest ranked options across all these stakeholder 
groups. This tendency towards common ground across such diverse 
perspectives arguably diminishes the queries that might otherwise very 
reasonably be raised about how sensitive these findings might be, to 
issues of perceived ‘representativeness’ with respect to variously- 
definable contrasting perspectives in appraisal. Analysis of dis-
aggregated perspectives in MCM does not escape the kinds of question 
that are always applicable with any kind of analysis of categorised social 
groupings (O’Neill, 2001). But where patterns across contrasting 
possible groupings display strong commonalities, then conclusions may 
be correspondingly more confident. 
6.2.3. Illumination of qualitative rationales and their application 
A core research question in this study, asked why it is that different 
options are variously favoured or not. Issues in this regard that came 
most prominently to the fore include perceptions of relative cost- 
effectiveness, or the challenging nature of effective co-ordination 
across complex innovation systems. The desirability for co-operation 
across public and private sectors was often raised, and there were also 
concerns that policies such as ‘protected markets’ and ‘enhance reve-
nues’ should not overly reward the private sector, particularly for 
products that might not sufficiently help to manage AMR. 
While it is arguably only appropriate to highlight here the most 
prominent themes (mentioned above) we note that the full list of reasons 
given to support or oppose particular options reveals both more common 
and rare, but still potentially important, caveats relating to the config-
uration of policies for particular situations. The extensive contextual 
information revealed by this study may be of value to policy makers 
concerned with the current and future contexts for the policy in-
struments they are seeking to establish. With this in mind, Annex D of 
the supplementary materials provides a checklist of prompts (based on 
all relevant points raised by interviewees) for policy makers engaged in 
the design of particular instruments. 
6.2.4. Relevance to the existing AMR policy literature 
The role of diagnostics in addressing the challenge of AMR is often 
overlooked (Ghani et al., 2015) or else held subsidiary to the goal of 
bringing new antibiotics into use (e.g. O’Neill, 2016). This study has 
demonstrated how policy could productively encourage innovation in 
diagnostic testing in order to better manage AMR. The study summarises 
the main types of policy options to stimulate diagnostic innovation, from 
a broad extant literature, and systematically appraises these through 
interviews with relevant experts. Naturally the resulting evidence sup-
ports the development of combinations of policies suitable for specific 
contexts. Factors that influence the performance of different policies are 
identified, which could enhance implementation and outcomes. While a 
uniform prescription is not supported, it is notable that the policy option 
that emerged in this process as tending to be more favoured, ‘incentivise 
use’, was relatively lacking in prominence in the extant policy literature. 
This family of instruments was only 6th out of 8, based on the 
literature-based tally summarised in Table 1 with policy options to 
‘make pathways’, ‘enhance revenues’, and ‘fund R&D’ being much more 
frequently mentioned. It is therefore all the more notable that a wide 
range of stakeholders from across a diversity of countries should broadly 
tend relatively to disfavour a number of policy options that are promi-
nent in the literature, by comparison with a particular policy option 
(‘incentivise use’) that is conventionally comparatively less attended to. 
Indeed, even in the industry subset (which might be thought the key 
beneficiary of those policies most emphasised in the extant policy 
literature), a high proportion of interviewees also tended quite strongly 
to favour ‘incentivise use’ over all the other appraised options. 
6.2.5. Limitations of this study 
As in any analysis of a complex, dynamic, uncertain and diverse field, 
this study displays a number of limitations associated with methodo-
logical design and implementation. One of these is the necessarily 
compressed account forced by the journal article format on the discus-
sion that is possible on methodological design and the nuances of find-
ings. Many features of the MCM process are necessarily side-lined here 
in order to set out the main focus of analysis. These are however pub-
lished in the MCM manual (Coburn et al., 2019). 
This said, one limitation that is often perceivable in ‘thick’ interpre-
tive or hybrid quantitative / qualitative research like this is that, by 
comparison with conventional statistical analysis, the number of in-
terviewees (47) is relatively small. Perhaps most pertinent here, is that 
the assumptions and norms of mainstream statistical analysis (themselves 
under increasing question nowadays (Ioannidis, 2005)(Cumming, 2014) 
(Mayo, 2018)) – like high ‘n’ and statistical representativeness – are not 
directly applicable to incommensurable methodologies like Q method or 
MCM (Stephenson, 1953; McKeown and Thomas, 1988; Coburn et al., 
2019). More relevant here are qualities discussed earlier (Section 4.2) 
relating to ‘non-probabilistic’ (Parker et al., 1998) ‘case study logic’ 
rather than ‘sampling logic’ (Yin, 2009) – of ‘validity’ (Mitchell, 1983), 
‘inclusiveness’ (O’Neill, 2001), ‘legitimacy’ (Chilvers, 2009) and ‘trans-
parency’ (Stirling, 2003) more than ‘statistical representativeness’ 
(Smith and Wales, 2000). 
It is important in MCM as in other in-depth methods to qualify that 
the merit orders discussed above for specific country perspectives, may 
each be strongly influenced by the conditions of elicitation. And it is 
here that correspondence reported between the merit orders derived 
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across all 47 interviews and those associated with specific perspectives 
within this, are suggestive of a reassuring degree of robustness for the 
findings that are the main emphasis in this article. However, as the 
analysis also shows, this overall merit order is not fully aligned with any 
particular subgroup of interviewees based on either country or stake-
holder perspective, so corresponding caution is required in applying 
overall results to any particular setting. 
It is intrinsic to this field, that a second legitimately perceivable 
limitation is, in some ways, of the opposite kind: that it can always be 
judged that some relevant stakeholder perspective has been excluded. 
For example, focusing as this study does on specialist understandings, 
both the ‘patient voice’ and the perspectives of distinguishable ‘publics’ 
are notably absent here. Of course, that such questions can be raised at 
all, reflects the relatively unusual transparency here (for policy appraisal 
in general), with regard to the inclusion of constituencies. And in this 
case, this exclusion reflects the lack of a strong patient or public voice in 
the national debates and committees around AMR in some countries 
(whatever this may imply). 
Thirdly, care was taken at interview to ensure interviewees all 
received the same introductory materials and facilitation by in-
terviewers. Nonetheless it is always the case in any method, that it 
cannot be excluded that detailed tacit interpretations adopted by indi-
vidual participants in different settings may attach contrasting detailed 
associations to terms used to describe the policy instruments. The care 
taken in MCM to document qualitative responses provides a check on 
this risk, but does not eliminate it. 
A fourth limitation arises from MCM interviews being highly sys-
tematically structured and taxing on individual deliberation by in-
terviewees, as well as being demanding on interviewers. It is as a result 
of this feature – and the principle that results will not be used in MCM 
unless the interviewee is fully confident that they adequately reflect 
their personal view – that data obtained in this study could not be used 
from three interviews (out of 50) because of implementation difficulties 
under the circumstances or in the time available. 
A fifth major limitation, of course, is the restrictive focus just on 
Western European states. This is all the more salient, because (despite 
some regional variations and global gaps in the available data (WHO, 
2017)), these have lower rates of AMR and more highly resourced 
healthcare services than many countries outside Europe (Collignon 
et al., 2018). The obvious remedy in this respect, is to complement this 
study with other work of broader reach. 
6.2.6. Further research 
The magnitude of the threat posed by AMR and the complexity of the 
required response strategies provide ample incentives for further studies 
on innovation policy in relation to the detection and treatment of drug 
resistant pathogens. For researchers also seeking to focus on the role of 
diagnostics, it may be informative to build on this study by consulting a 
wider range of individuals to confirm these results in particular national 
settings. Looking beyond the European countries studied here, similar 
studies may be needed for other countries, particularly in resource poor 
settings where AMR is most prevalent and deadly and where perhaps the 
policy instruments required differ from those favoured in the large Eu-
ropean economies predominant in the sample studied here. It is 
important to recognise that the management of AMR amounts to a global 
and intergenerational arms race between humans and microbial path-
ogens, requiring significant investments in diagnostic innovation. It is 
therefore appropriate to monitor the mix of policy instruments applied 
to manage diagnostic innovation focused on AMR, and it may also be 
relevant to study the sequencing of interventions over the long term 
(Cunningham et al., 2013). 
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